Simple Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy
associated with poor prognosis. Treatment options are limited partially due to resistance to …

Immune evasion is key to cancer initiation and later at metastasis, but its dynamics at
intermediate stages, where potential therapeutic interventions could be applied, is …

Purpose: Innate immunity is an indispensable arm of tumor immune surveillance, and the
liver is an organ with a predominance of innate immunity, where mucosal-associated …

BACKGROUND AND AIMS Programmed death 1 (PD‐1) checkpoint inhibition has shown
promising results in patients with hepatocellular carcinoma, inducing objective responses in …

Introduction: Although immune checkpoint inhibitors (ICIs) have been considered as
promising agents for the treatment of advanced hepatocellular carcinoma (HCC), previous …

Immune checkpoint inhibition suggests promising progress for the treatment of advanced
hepatocellular carcinoma (HCC). However, the underlying cellular mechanisms remain …

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a high rate of mortality
and recurrence. N6-methyladenosine methylation (m6A) is the most common modification to …

Cancer immunotherapy is the new generation and widely accepted form of tumour
treatment. It is, however, associated with exclusive challenges which include organ-specific …

Objective Identify the prognostic value and investigate the association between programmed
cell death 1 (PDCD1) gene expression and immune infiltration in pan-cancer. Methods We …

The combination of atezolizumab plus bevacizumab (atezo/bev) has dramatically changed
the treatment landscape of advanced HCC (aHCC), achieving durable responses in some …